Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience today reported a 1 percent decline in revenues for its fiscal third quarter. 

For the three months ended June 30, Meridian posted $50.1 million in revenues, down from $50.7 million in the year-ago period but above the consensus Wall Street estimate of $49.2 million. 

The company's life science segment saw revenues grow 8 percent to $14.2 million from $13.1 million, while the diagnostics segment saw a 4 percent decline in revenues to $35.9 million from $37.5 million. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.